 Zacks Investment Research upgraded shares of Aimmune Therapeutics NASDAQ:AIMT from a hold rating to a buy rating in a research note published on Thursday morning, Zacks.com reports. The firm currently has 18.00 price target on the biotechnology companys stock. According to Zacks, Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development ... 